Table 1.

Sociodemographic and Clinical Characteristics of Sample (n=278)

Group assignment (n, %)
Group A	216	78%
Group B	36	13%
Group C	26	9%
Mean age: years (SD)	50.50	12.52
Mean education: years (SD)	13.94	2.72
Gender (n, % female)	124	45%
Race/ethnicity (n, % Caucasian/non-Hispanic)	225	81%
Marital status (n, % married)	211	76%
Annual household income (n, % > $40k)	154	55%
HCT type (n, % allogeneic)	65	23%
Unrelated donor (n, %)	21	32% a
Mismatched donor (n, %)	2	3% a
Matched sibling (n, %)	42	65% a
Disease type
Acute myelogeneous leukemia	20	7%
Myelodysplastic syndrome	8	3%
Acute lymphoblastic leukemia	9	3%
Multiple myeloma	150	54%
Chronic lymphocytic leukemia	2	1%
Chronic myelogeneous leukemia	7	3%
Myeloproliferative disorder	2	1%
Non-Hodgkin’s lymphoma	60	22%
Aplastic anemia	3	1%
Hodgkin’s lymphoma	17	6%
History of prophylactic cranial irradiation (n, % yes)	6	2%
History of total body irradiation (n, % yes)	15	5%
History of intrathecal chemotherapy (n, % yes)	17	6%
Median number of previous chemotherapy regimens (range)	2	0–7
Peak severity of post-HCT mucositis (n, % grade 3 or 4)	200	72%
Peak severity of post-HCT enteritis (n, % grade 3 or 4)	106	38%
Days to engraftment (median, range)	12	9–39
Length of hospital stay (median in days, range)	19	0–96
Disease relapse at 6 months (n, % yes)	12	10%
Active GVHD at 6 months (n, % yes)	10	15%a
Prescribed steroids at 6 months (n, % yes)	17	16%
Prescribed narcotics at 6 months (n, % yes)	35	33%
Disease relapse at 12 months (n, % yes)	15	19%
Active GVHD at 12 months (n, % yes)	5	8% a
Prescribed steroids at 12 months (n, % yes)	14	20%
Prescribed narcotics at 12 months (n, % yes)	17	24%

^aDenominator is participants with allogeneic transplant.